Skip to content
mielomamultiplo.com · Multiple Myeloma
Emergency 112  · SNS 24 808 24 24 24
The Multiple Myeloma symbol — find out what it means

Multiple Myeloma There is hope. There is a way forward.

information · support · hope

It is always better to be an informed patient.

News, testimonies, a space to share ideas and links that help patients and carers understand the disease better and know where to find help.

Automatic translation by MielomaAI. The original text is in Portuguese. Some parts may still appear in Portuguese while they are being translated. Português
Summary · Access to medicines, prices and funding

Recent developments regarding multiple myeloma highlight advances in access to medications and funding. [Brazil] Tocantins has incorporated daratumumab into treatment, while [Portugal] the SNS has begun to fund new therapeutic combinations. The approval of medications such as Iberdoma [USA] and the expansion of the Melflufen monograph [USA] are also important milestones.

Made by MielomaAI On November 17, 2026, at 10:32, from recent news. May contain errors. View news →

How much treatment costs

In Portugal, multiple myeloma treatment in SNS hospitals — including CAR-T — is not paid for by the patient. Showing the cost helps explain why access takes time and why price negotiations with pharmaceutical companies matter so much.

0 €what the patient pays for the medicine in the SNS
~350 mil €cost of one CAR-T treatment in Europe
+19%rise in Carvykti's US list price between 2022 and 2025 (today about €502,452)
What it cost then and what it costs now (USA)

The USA is the only country where the list price is public. Since launch, the price of both CAR-T for myeloma has gone up every year.

350 mil €400 mil €450 mil €500 mil €20212022202320242025Abecma (ide-cel) 2021: €379,569Abecma (ide-cel) 2022: €379,569Abecma (ide-cel) 2023: €413,731Abecma (ide-cel) 2024: €450,966Abecma (ide-cel) 2025: €478,024478.024 €379.569 €Abecma (ide-cel)Carvykti (cilta-cel) 2022: €420,738Carvykti (cilta-cel) 2023: €420,738Carvykti (cilta-cel) 2024: €441,076Carvykti (cilta-cel) 2025: €502,452502.452 €420.738 €Carvykti (cilta-cel)

US list price per treatment (single dose), before discounts, converted to euros. Amounts converted to euros: €1 = 1.1052 dollars and 6.1748 reais (European Central Bank reference rates of 13/11 and 09/11/2026) and 0.8336 pounds (market rate of 05/11/2026). The original amounts are in the sources. Abecma was launched in March 2021 and Carvykti in February 2022. Source: Pulice & Schulman, Health Management, Policy and Innovation, 2026 ↗

In 2021 the independent US institute ICER calculated that Abecma needed a discount of 37% to 54% to have a fair price for its benefit. Source: Fierce Pharma ↗

In Europe and in Portugal
Portugal 2019350.000 €IPO Porto355.165 €Spain 2025–26353.000 €

Spain: the two Madrid contracts (€2,823,999.97 in December 2025 and €1,058,999.99 in June 2026, excluding VAT) are exact multiples of €353,000, which points to that price per treatment. The contracts do not state the number of treatments.

Portugal and Carvykti. Infarmed approved public funding of Carvykti on 26 May 2025. In its assessment it concluded that the medicine was not cost-effective at the price asked and recommended a substantial price reduction; a negotiation followed. The final price is confidential, as usual. Source: Infarmed ↗

Where the money goes
CAR-T medicine: 97%Hospital stay, tests and side effects: 3%

In the IPO Porto study, the medicine accounted for 97% of the total cost per patient. Source: PLOS ONE (2022) ↗

Costs left for the family. Even with treatment paid for by the SNS, there are expenses: travel, staying near the hospital in the first four weeks, the carer's time and time off work. Talk to the hospital social worker and to patient associations (APCL, APLL, Portuguese League Against Cancer) about the support available.

Figures from public sources; the actual prices paid by hospitals include confidential discounts and may be lower. Information page, not financial advice.

Latest news on access, pricing and funding

All news → · Summaries created by MielomaAI; expand the article to read the original.